Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0011570 (depression)
 172,036 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Iodixanol, a new ratio 6 nonionic iodinated contrast agent with an osmolality equal to serum, was compared with iohexol in a randomized, double-blind, parallel study. Two hundred patients undergoing elective diagnostic cardiac angiography were randomized to iodixanol (n = 101) or iohexol (n = 99). There were no differences noted between the 2 agents in the mean changes in systolic or diastolic blood pressure or heart rate during or immediately after any angiography. However, significantly more patients had a decrease in diastolic blood pressure of > 20 mm Hg during left coronary angiography with iodixanol. The only significant differences in any electrophysiologic parameter were slightly more PR prolongation during left coronary angiography with iodixanol and more ST-segment depression with iohexol during coronary angiography. Neither was clinically significant. Injection-associated discomfort occurred with both agents, but more patients experienced moderate to severe discomfort with iohexol (52%) than with iodixanol (17%) (p < 0.001). Only 1 potentially serious adverse event, ventricular fibrillation with iohexol, was considered related to contrast, and there were no differences noted between the agents. Overall, angiographic quality was equal with all angiograms being assessed as good or excellent in both groups (p = 0.885). In this low-risk population undergoing cardiac angiography, iodixanol is safe and effective without clinically important differences from iohexol. Additional studies in patients at high risk for complications should help further define the role of iodixanol in cardiac angiography.
 ...
PMID:Iodixanol, a new isosmotic nonionic contrast agent compared with iohexol in cardiac angiography. 801 8

Since the first animal coronary arteriogram in 1933 there have been many innovations in techniques and contrast media. From 1933 through the late 1950s the procedures used involved nonselective aortic injections and the use of acetylcholine to slow the heart. The first selective coronary arteriogram in animals was performed by West, Kobayashi & Guzman in 1958 (45) and in 1959 Guzman & West (7) observed ventricular fibrillation with some media but not others. In 1967 Judkins (14) described the catheter designs for right and left coronary catheterizations that we still use today. In the 1970s and 80s many authors observed the ionic monomeric contrast media reduced plasma calcium causing fibrillation and myocardial depression. Supplementation of ionic media with calcium was shown to moderate these adverse effects. Almen's vision of low osmolality contrast media and the creation of metrizamide (1) stimulated the rapid development of monomeric and dimeric nonionic contrast media. The ionic dimeric medium ioxaglate also provided low osmolality. Digital frame grabbers and computers lead to the development of digital subtraction angiography and new applications of arteriography, frequently using dilute media. Unexpectedly, during prolonged right coronary arteriography in animals, dilute nonionic media were found to produce increased fibrillation as compared to dilute ionic media. The addition of sodium to nonionic media significantly reduced the incidence of fibrillation. Animal studies with the nonionic medium iodixanol supplemented with sodium and calcium (Visipaque) have demonstrated minimal incidences of fibrillation and myocardial depression.
 ...
PMID:A review of coronary arteriography- and contrast media-induced ventricular fibrillation. 861 May 3

Changes in contractile function induced by modern roentgen contrast media (CM) were examined in isolated rat hearts. Four coronary perfusions were undertaken in each heart with increasing volumes of each CM in order to test a wider spectrum of potential side-effects. Left ventricular developed pressure (LVDP) and heart rate (HR) were recorded. Six commercially available or investigational CM were examined: A, Hexabrix (ioxaglate 320 mg I/ml, Na 146 mM); B, Iosvist (iotrolan 300 mg I/ml, Na 6 mM);C, Visipaque (iodixanol 320 mg I/ml, Na 19 mM, Ca 0.3 mM); D, "Iodixanol high Ca-Mg" (iodixanol 320 mg I/ml, Na 19 mM, Ca 1.2 mM, Mg 0.6 MM); E, "Iohexol I 350" (iohexol 350 mg I/ml, Na 28 mM); and F, "Iohexol I 150" (iohexol 150 mg I/ml Na 28 mM). A, E and F were low-osmolal (400-940 mosm/kg H2O) CM whereas B, C and D were essentially isosmolal. Contractile changes (transient LVDP depression) was volume-dependent. Maximal values for LVDP depression were "Iohexol I 150" 11-22%<Iosovist 13-45% and Visipaque 18-45%<"Iodixanol high Ca-Mg" 14-62%<"Iohexol I 350" 40-76%<Hexabrix 92-96%. No changes observed in HR. The study revealed that cardiac function was hardly affected by CM which had the following characteristics: a low to normal osmolality (<400 mosm/kg H2O); a low concentration of contrast agent (150 mg I/ml); and an overall content of ions (Na 6-28 mM, Ca 0-0.3 mM) complying well with myocardial ratios of Na and Ca. Of the CM tested that may be in clinical use in coronary angiography (300-350 mg I/ml), Iosvist and Visipaque induced the least changes in contractibility.
 ...
PMID:Changes in contractile function with low-osmolal and isosmolal contrast media for coronary angiography. 861 May 7